Acute Ischemic Stroke
Conditions
Keywords
Stroke, Large Vessel Occlusion, Mechanical Thrombectomy, Neurovascular Intervention
Brief summary
The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.
Detailed description
The purpose of this prospective, open label clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System as frontline approach in the treatment of large vessel occlusions in patients experiencing Acute Ischemic Stroke within 8 hours of symptom onset or last seen normal. The target sample size for this clinical trial is 170 subjects enrolled in up to 30 sites globally. The maximum number of subjects that may be enrolled is 340. Subjects will undergo mechanical thrombectomy procedure and will have postoperative assessments completed at 24 hours and on day 5-7 or hospital discharge (whichever comes first). The final study visit will occur approximately 90 days after the index event. The primary effectiveness endpoint is the proportion of patients who achieve First Pass Reperfusion Effect (FPE) as defined by modified treatment in cerebral infarction score (mTICI) ≥ 2c after the first pass as assessed by an independent Imaging Core Lab. The primary safety endpoint is the proportion of patients with symptomatic ICH (sICH) at 24 hours post-thrombectomy as assessed by a central events committee (CEC).
Interventions
The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulseTM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.
Sponsors
RapidPulse, Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 to 80 years * Clinical diagnosis of acute ischemic stroke with NIH Stroke Scale (NIHSS) score ≥ 6 * Able to be treated within 8 hours of symptom onset or last known normal (LKN) * Able to be treated within 120 minutes from the time of the qualifying baseline CT/MR image * Pre-morbid Modified Rankin Scale (mRS) score 0-1 * Angiographic confirmation of large vessel occlusion (LVO) in the anterior (intracranial ICA or MCA M1 or M2 segments) or posterior circulation (vertebral or basilar arteries) as confirmed by digital subtraction angiography (DSA) irrespective of IV thrombolysis administration * Candidate to receive treatment with ADAPT technique (Direct Aspiration First-Pass Technique)
Exclusion criteria
* Intracranial Hemorrhage (ICH) * Alberta Stroke Program Early CT Score (ASPECTS) \<6 * Intracranial Atherosclerotic Disease (ICAD) * Multiple or tandem occlusions * Life expectancy less than 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of First Pass Reperfusion Effect (FPE) | Intra-procedural | The proportion of patients who achieve First Pass Reperfusion Effect (FPE) as defined by mTICI ≥ 2c after the first pass |
| Rate of symptomatic intracranial hemorrhage (sICH) | Post-procedural (24 hours post-thrombectomy) | The proportion of patients with symptomatic ICH (sICH) at 24 hours post-thrombectomy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of reperfusion after all study device passes | Intra-procedural | Proportion of patients who achieve mTICI ≥ 2b within a maximum of 3 passes with Study Device |
| Modified Rankin Scale (mRS) at 90 days post treatment | Post-procedure (90 days post-thrombectomy) | Proportion of patients who achieve mRS ≤2 at 90-days post treatment. |
Countries
France, Spain, Turkey (Türkiye), United States
Contacts
CONTACTCynthia Yang
PRINCIPAL_INVESTIGATORRaul G Nogueira, MD
University of Pittsburgh Medical Center Stroke Institute
PRINCIPAL_INVESTIGATORMarc Ribó, MD
Hospital Universitari Vall d' Hebron
Outcome results
None listed